Lecia V Sequist

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!
    Lecia V Sequist
    J Clin Oncol 21:3186-8. 2003
  2. ncbi Epidermal growth factor receptor mutation testing in the care of lung cancer patients
    Lecia V Sequist
    Cancer Center and Department of Medicine, Massachusetts General Hospital, and Laboratory for Molecular Medicine, Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 12:4403s-4408s. 2006
  3. ncbi First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit St, Yawkey Suite 7B, Boston, MA 02114, USA
    J Clin Oncol 26:2442-9. 2008
  4. ncbi Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1170-3. 2009
  5. ncbi EGFR tyrosine kinase inhibitors in lung cancer: an evolving story
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Annu Rev Med 59:429-42. 2008
  6. ncbi The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    J Thorac Oncol 4:281-3. 2009
  7. ncbi Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1389-96. 2009
  8. ncbi Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors
    Nathan A Pennell
    Massachusetts General Hospital and Harvard Medical School, MGH Cancer Center, 32 Fruit Street, Yawkey 7B, Boston, MA, USA
    Biomark Med 1:203-7. 2007
  9. ncbi Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit Street, Yawkey Suite 7B, Boston, Massachusetts 02114, USA
    Oncologist 12:325-30. 2007
  10. ncbi Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 28:3076-83. 2010

Detail Information

Publications55

  1. ncbi Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!
    Lecia V Sequist
    J Clin Oncol 21:3186-8. 2003
  2. ncbi Epidermal growth factor receptor mutation testing in the care of lung cancer patients
    Lecia V Sequist
    Cancer Center and Department of Medicine, Massachusetts General Hospital, and Laboratory for Molecular Medicine, Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 12:4403s-4408s. 2006
    ..It is likely that mutation testing and other molecular analyses will be most useful in these two clinical situations...
  3. ncbi First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit St, Yawkey Suite 7B, Boston, MA 02114, USA
    J Clin Oncol 26:2442-9. 2008
    ..The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms...
  4. ncbi Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1170-3. 2009
    ..7 months, and median overall survival was 3.9 months. We found that biweekly pemetrexed and gemcitabine was too toxic in our cohort of elderly patients with newly diagnosed advanced non-small cell lung cancer...
  5. ncbi EGFR tyrosine kinase inhibitors in lung cancer: an evolving story
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Annu Rev Med 59:429-42. 2008
    ..This review summarizes the clinical development of EGFR tyrosine kinase inhibitors, the discovery of molecular predictors of response, and the future directions for research in the field...
  6. ncbi The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    J Thorac Oncol 4:281-3. 2009
    ..Here, we review the development and initial clinical studies with a novel microfluidic platform for isolating these cells, the CTC-chip, and discuss its potential uses in the study of lung cancer...
  7. ncbi Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1389-96. 2009
    ..We aimed to evaluate the safety and efficacy of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer...
  8. ncbi Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors
    Nathan A Pennell
    Massachusetts General Hospital and Harvard Medical School, MGH Cancer Center, 32 Fruit Street, Yawkey 7B, Boston, MA, USA
    Biomark Med 1:203-7. 2007
    ..The paper by Hirsch and colleagues will be discussed and compared with other studies of potentially useful EGFR biomarkers...
  9. ncbi Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit Street, Yawkey Suite 7B, Boston, Massachusetts 02114, USA
    Oncologist 12:325-30. 2007
    ..This review discusses four promising agents that are currently being studied in NSCLC: EKB-569, HKI-272, CI-1033, and ZD6474...
  10. ncbi Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 28:3076-83. 2010
    ..Resistance emerges after 9 to 12 months, primarily mediated by the T790M resistance mutation. We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M...
  11. ncbi Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School Partners Healthcare Center for Genetics and Genomics, MGH Department of Pathology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Oncologist 12:90-8. 2007
    ..6 years in mutation-negative patients, after adjusting for age, gender, and stage at diagnosis. Integrating molecular profiling into clinical care is feasible in NSCLC patients and provides useful clinical information...
  12. ncbi Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Sci Transl Med 3:75ra26. 2011
    ..Collectively, these results deepen our understanding of resistance to EGFR inhibitors and underscore the importance of repeatedly assessing cancers throughout the course of the disease...
  13. ncbi Update on epidermal growth factor receptor inhibitor development in lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    J Thorac Oncol 1:740-3. 2006
    ..We summarize updates on EGFR targeted therapies that were presented during the sixth annual Targeted Therapies for the Treatment of Lung Cancer Conference in Los Angeles, CA; January 27-28, 2006...
  14. ncbi Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 28:4953-60. 2010
    ..We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC)...
  15. ncbi Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 29:3307-15. 2011
    ..This global, randomized phase II trial examined erlotinib plus tivantinib (ARQ 197; ArQule, Woburn, MA), a novel MET inhibitor...
  16. ncbi Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
    L V Sequist
    Massachusetts General Hospital Cancer Center, Boston, USA
    Ann Oncol 22:2616-24. 2011
    ..Personalizing non-small-cell lung cancer (NSCLC) therapy toward oncogene addicted pathway inhibition is effective. Hence, the ability to determine a more comprehensive genotype for each case is becoming essential to optimal cancer care...
  17. ncbi Treatment of advanced non-small cell lung cancer in the elderly
    Lecia V Sequist
    Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Semin Respir Crit Care Med 26:289-97. 2005
    ..As the U.S. population ages and the incidence of NSCLC rises, an understanding of treatment options for elderly patients with NSCLC is vital for all clinicians involved in their clinical care...
  18. ncbi First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S143-5. 2008
    ..This review summarizes the data describing the use of EGFR tyrosine kinase inhibitors in a genotype-directed population of NSCLC patients with EGFR mutations and discusses areas that require further study...
  19. ncbi Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
    Daniel B Costa
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7060-7. 2008
    ..Our goal was to determine the effects of erlotinib 150 mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib is given at a higher biologically active dose than gefitinib...
  20. ncbi Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    David M Jackman
    Lowe Center of Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3908-14. 2006
    ..Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib...
  21. ncbi Detection of mutations in EGFR in circulating lung-cancer cells
    Shyamala Maheswaran
    Massachusetts General Hospital Cancer Center, Boston 02129, USA
    N Engl J Med 359:366-77. 2008
    ..Molecular characterization of circulating tumor cells may provide a strategy for noninvasive serial monitoring of tumor genotypes during treatment...
  22. ncbi Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC
    Raymond H Mak
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Oncologist 16:886-95. 2011
    ..Epidermal growth factor receptor (EGFR) mutations identify a unique biological subtype of non-small cell lung cancer (NSCLC). Treatment outcomes for EGFR-mutant locally advanced NSCLC patients have not been well described...
  23. ncbi Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Joel W Neal
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Thorac Oncol 5:1855-8. 2010
    ..Cetuximab is a monoclonal antibody against the EGFR receptor with antitumor activity in NSCLC. This study evaluated the efficacy of cetuximab monotherapy after prior treatment with an oral EGFR tyrosine kinase inhibitor (TKI)...
  24. ncbi EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
    April F Eichler
    Pappas Center for Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Neuro Oncol 12:1193-9. 2010
    ..70-6.41) were independently associated with survival. In NSCLC patients with BM, EGFR mutation status is associated with improved survival, independent of age, functional status, extracranial disease status, and number of BMs...
  25. ncbi A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer
    Rebecca Suk Heist
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Thorac Oncol 3:1153-8. 2008
    ..We investigated the activity and tolerability of the combination of oxaliplatin, pemetrexed, and bevacizumab in patients with previously treated advanced NSCLC...
  26. ncbi Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials
    David M Jackman
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:5267-73. 2009
    ....
  27. ncbi A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:1602-8. 2012
    ..This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer...
  28. ncbi Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02129, USA
    Clin Cancer Res 11:5668-70. 2005
  29. ncbi Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 25:587-95. 2007
    ....
  30. ncbi Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
    Shannon L Stott
    Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 107:18392-7. 2010
    ..In a subset of patient samples, the low shear design of the HB-Chip revealed microclusters of CTCs, previously unappreciated tumor cell aggregates that may contribute to the hematogenous dissemination of cancer...
  31. ncbi Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features
    Karin E Finberg
    Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Mol Diagn 9:320-6. 2007
    ..Therefore, our data suggest that EGFR sequence analysis could be avoided in BAC/AWBF when true mucinous morphology is identified, avoiding the associated testing costs...
  32. ncbi Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment
    Tan Min Chin
    Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 14:6867-76. 2008
    ..NSCLC-derived cell lines have provided a powerful system for modeling EGFR mutation-correlated sensitivity to EGFR inhibitors and for modeling mechanisms of acquired drug resistance that are observed clinically...
  33. ncbi Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Thorac Oncol 5:1637-43. 2010
    ..AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. A phase I/II study was conducted combining AT-101 with topotecan in relapsed and refractory SCLC...
  34. ncbi FGFR1 amplification in squamous cell carcinoma of the lung
    Rebecca S Heist
    Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 7:1775-80. 2012
    ..Little is known, however, about the clinical and demographic correlates of FGFR1 amplification...
  35. ncbi Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  36. ncbi Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
    Min Yu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Science 339:580-4. 2013
    ..These data support a role for EMT in the blood-borne dissemination of human breast cancer...
  37. ncbi Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 4:120ra17. 2012
    ....
  38. ncbi Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung
    Lecia V Sequist
    Cancer Center, Massachusetts General Hospital, USA
    N Engl J Med 359:405-14. 2008
  39. ncbi Non-small cell lung cancer in octogenarians: treatment practices and preferences
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Thorac Oncol 2:1029-35. 2007
    ..Treatment practices in this patient population are poorly described. In this report, we describe the treatment of a population of very elderly patients with NSCLC at a large teaching hospital...
  40. ncbi Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Thomas J Lynch
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S107-12. 2008
    ..A CME activity based on this summary is also available at www.informedicalcme.com/cme...
  41. ncbi Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology/Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  42. ncbi Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer
    David T Miyamoto
    Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA
    Cancer Discov 2:995-1003. 2012
    ..Measurement of pre- and posttreatment AR signaling within CTCs may help target such treatments to patients most likely to respond to second-line therapies...
  43. ncbi Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer
    Raymond H Mak
    Harvard Radiation Oncology Program, Boston, MA, USA
    Oncologist 16:319-26. 2011
    ..To compare (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) imaging characteristics in non-small cell lung cancer (NSCLC) with or without epidermal growth factor receptor (EGFR) mutations...
  44. ncbi First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations
    Joel W Neal
    Dana Farber Partners CancerCare Hematology and Oncology Program, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 8:119-26. 2010
    ..Here, we review the studies supporting the use of EGFR tyrosine kinase inhibitors in the frontline setting in patients with EGFR mutations...
  45. ncbi Isolation of rare circulating tumour cells in cancer patients by microchip technology
    Sunitha Nagrath
    Surgical Services and BioMEMS Resource Center, Massachusetts General Hospital, Harvard Medical School, and Shriners Hospital for Children, Boston, Massachusetts 02114, USA
    Nature 450:1235-9. 2007
    ..It has broad implications in advancing both cancer biology research and clinical cancer management, including the detection, diagnosis and monitoring of cancer...
  46. ncbi BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
    Anthony C Faber
    Massachusetts General Hospital Cancer Center, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02129, USA
    Cancer Discov 1:352-65. 2011
    ..These findings suggest assessment of BIM levels in treatment-naïve tumor biopsies may indicate the degree of benefit from single-agent kinase inhibitors in multiple oncogene-addiction paradigms...
  47. ncbi Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers
    Hihu Wing Cheung
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Discov 1:608-25. 2011
    ....
  48. ncbi Genetic changes in squamous cell lung cancer: a review
    Rebecca S Heist
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:924-33. 2012
    ....
  49. ncbi Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
    Dora Dias-Santagata
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    EMBO Mol Med 2:146-58. 2010
    ..This work therefore establishes a platform for real-time targeted genotyping that can be widely adopted. We expect that efforts like this one will play an increasingly important role in cancer management...
  50. ncbi Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells
    Emre Ozkumur
    Massachusetts General Hospital Center for Engineering in Medicine, Harvard Medical School, Boston, MA 02114, USA
    Sci Transl Med 5:179ra47. 2013
    ....
  51. ncbi A new BATTLE in the evolving war on cancer
    Lecia V Sequist
    Harvard Medical School, Boston, Massachusetts, USA
    Cancer Discov 1:14-6. 2011
    ..The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial couples real-time molecular interrogation of cancer specimens with an adaptive Bayesian clinical trial design...
  52. ncbi RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis
    Min Yu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Nature 487:510-3. 2012
    ..Thus, molecular analysis of CTCs may identify candidate therapeutic targets to prevent the distal spread of cancer...
  53. ncbi Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
    Clin Cancer Res 13:s4583-8. 2007
    ....
  54. ncbi Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer
    Shannon L Stott
    Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Sci Transl Med 2:25ra23. 2010
    ....
  55. ncbi Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
    John G Gribben
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 106:4389-96. 2005
    ..From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens...